.

Type 1 Diabetes TrialNet at Vanderbilt

New Onset Studies for those diagnosed with Type 1 Diabetes within the past three months

At the time of diagnosis. approximately 15% of the beta cells of the pancreas continue to produce insulin. Even though these cells cannot produce enough insulin to keep the blood sugars within normal range, they have been shown to decrease serious low blood sugars (serious hypoglycemic events) and the long-term complications of the disease.
 
The new onset studies are designed to preserve the insulin secretion in people newly diagnosed with type 1 diabetes.
 
Vanderbilt Eskind Diabetes Clinic currently has one new onset study with Type 1 Diabetes TrialNet.   The purpose of this study is to learn if the medication, abatacept, is safe and effective and can help people with newly diagnosed T1D by delaying or stopping further destruction of beta cells.  We have currently met our enrollment capacity.
 
If you are interested in other new onset studies, we will assist with referring to our TrialNet partners at other sites. Please email: diabetesresearch@vanderbilt.edu and specify in the subject line that you are interested in a new onset study.
 
If you are interested in participating or would like more information:
 
Contact
Anne Brown or Margo Black
615-936-7NEW or 936-TNET or 888-VU4-TNET
(Please specify interest in new onset studies)

This page was last updated February 4, 2011 and is maintained by